CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionP/E ratio is 212×, higher than 95% of its Medical Devices peers (median 31.99×)
- FinancialsAltman Z-Score 4.02: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.29%Below 5Y avg (1.00%)
Annual Rate
CNY 0.05Paid annual
Payout Ratio
131.4%High
Last Ex-Dividend
Sep 3, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.75BCNY410.67M · vs all stocks (USD)
Trailing P/E
212.00xvs Medical Devices peers
Revenue (TTM)
392.11MCNY58.51M · vs all stocks (USD)
Profit Margin
3.14%vs Medical Devices peers
Beta
0.2840xvs all stocks
52-Week Change
-30.46%vs all stocks
Market Capitalization
2.75BCNY410.67M · vs all stocks (USD)
Enterprise Value
2.50BCNY373.42M · vs all stocks (USD)
Trailing P/E
212.00xvs Medical Devices peers
Forward P/E
20.19xvs Medical Devices peers
Price to Sales (TTM)
7.02xvs Medical Devices peers
Price to Book (MRQ)
1.88xvs Medical Devices peers
Enterprise to Revenue
6.38xvs Medical Devices peers
Enterprise to EBITDA
36.38xvs Medical Devices peers
Gross Margin
68.74%vs Medical Devices peers
Profit Margin
3.14%vs Medical Devices peers
Operating Margin
22.26%vs Medical Devices peers
Return on Assets (TTM)
0.77%vs Medical Devices peers
Return on Equity (TTM)
0.65%vs Medical Devices peers
Revenue (TTM)
392.11MCNY58.51M · vs all stocks (USD)
Revenue per Share (TTM)
2.41CNYUpdated Sep 21, 2026Quarterly Revenue Growth
24.40%vs Medical Devices peers
Gross Profit (TTM)
264.42MCNY39.46M · vs all stocks (USD)
EBITDA (TTM)
88.49MCNY13.20M · vs all stocks (USD)
Net Income (TTM)
12.31MCNY1.84M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
644.80%vs Medical Devices peers
Operating Cash Flow (TTM)
180.67MCNY26.96M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
86.50MCNY12.91M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0500CNYUpdated Sep 21, 2026Trailing Annual Dividend Yield
0.29%vs all stocks
5-Year Average Dividend Yield
1.00%vs all stocks
Payout Ratio
131.41%vs Medical Devices peers
Minority Interest (Equity)
54.02MCNYFY2025 · Dec 31, 2025Revenue
363.83MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
110.76MCNYFY2025 · Dec 31, 2025Gross Profit
253.07MCNYFY2025 · Dec 31, 2025Operating Income
38.50MCNY5.75M · vs all stocks (USD)
Pre-tax Income
-2.88MCNYFY2025 · Dec 31, 2025Income Tax Expense
-2.06MCNYFY2025 · Dec 31, 2025Net Income
-824.40KCNYFY2025 · Dec 31, 2025EBIT
-317.58KCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
88.49MCNYFY2025 · Dec 31, 2025Research & Development
58.46MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
35.21MCNYFY2025 · Dec 31, 2025Other Operating Expenses
4.19MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.47MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
2.56MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0220CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0220CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
163.09MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
163.09MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-824.40KCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
4.41MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
63.74MCNYFY2025 · Dec 31, 2025Free Cash Flow
-3.45MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
380.90MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-824.40KCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.41MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
59.25MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
900.52KCNYFY2025 · Dec 31, 2025Capital Expenditures
-67.19MCNYFY2025 · Dec 31, 2025Net Acquisitions
-263.93MCNYFY2025 · Dec 31, 2025Purchase of Investments
-633.66MCNYFY2025 · Dec 31, 2025Sale of Investments
673.71MCNYFY2025 · Dec 31, 2025Other Investing Activity
7.09MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-283.99MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
287.14MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-5.99MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-28.84MCNYFY2025 · Dec 31, 2025Other Financing Charges
-27.41MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
224.91MCNYFY2025 · Dec 31, 2025Shares Outstanding
162.27MSharesUpdated Sep 21, 2026Float Shares
112.49MSharesUpdated Sep 21, 2026% Held by Insiders
34.97%vs all stocks
% Held by Institutions
9.92%vs all stocks
Total Cash (MRQ)
662.23MCNY98.82M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.15CNYUpdated Sep 21, 2026Total Debt (MRQ)
420.20MCNY62.70M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2848xvs Medical Devices peers
Current Ratio (MRQ)
6.68xvs Medical Devices peers
Book Value per Share (MRQ)
9.01CNYUpdated Sep 21, 2026Total Assets
2.06BCNY306.92M · vs all stocks (USD)
Total Current Assets
960.33MCNYFY2025 · Dec 31, 2025Total Liabilities
576.38MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.10BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
380.92MCNYFY2025 · Dec 31, 2025Total Current Liabilities
195.46MCNYFY2025 · Dec 31, 2025Cash
377.36MCNYFY2025 · Dec 31, 2025Cash Equivalents
8.72MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
386.08MCNYFY2025 · Dec 31, 2025Other Short-term Investments
170.57MCNYFY2025 · Dec 31, 2025Accounts Receivable
204.46MCNYFY2025 · Dec 31, 2025Inventory
98.51MCNYFY2025 · Dec 31, 2025Accounts Payable
78.57MCNYFY2025 · Dec 31, 2025Short-term Debt
33.08MCNYFY2025 · Dec 31, 2025Other Current Liabilities
1.42MCNYFY2025 · Dec 31, 2025Long-term Debt
367.66MCNYFY2025 · Dec 31, 2025Common Stock (Book)
162.54MCNYFY2025 · Dec 31, 2025Retained Earnings
787.13MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.48BCNY220.91M · vs all stocks (USD)
Treasury Stock
49.02MCNYFY2025 · Dec 31, 202552-Week Low
11.04CNYUpdated Sep 21, 202652-Week High
30.00CNYUpdated Sep 21, 202652-Week Change
-30.46%vs all stocks
Beta
0.2840xvs all stocks
50-Day MA
14.58CNYUpdated Sep 21, 2026200-Day MA
16.22CNYUpdated Sep 21, 2026Avg 10-Day Volume
21.10MSharesUpdated Sep 21, 2026Avg 30-Day Volume
18.49MSharesUpdated Sep 21, 2026Diluted EPS (TTM)
0.0800CNYUpdated Sep 21, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Where is this company structurally exposed?
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
P/E ratio is 212×, higher than 95% of its Medical Devices peers (median 31.99×)Significant
P/E ratio: 212Industry median: 31.99Industry P95: 189.554Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.69Profit Margin: 0.03
Financial Health
Altman Z-Score 4.02: safe zoneNotable
Altman Z-Score: 4.02
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Aarti Drugs Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Relmada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Canopus Wisdom MedTech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Goto Biopharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
AP Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Kamada Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yantai Zhenghai Bio-Tech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Novartis India Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Wuxi Quechen Silicon Chemical Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Suzhou Kingswood Education Technology Co., Ltd.
1 interpretationIndustry-Benchmarked ROA and Margin Elevated
Skyworks Solutions Inc.
1 interpretationDown-Close Share With Multi-Year Earnings Decrease